Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The company will imminently start its third pivotal trial of PF-08634404.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
